Tengteng Wang1, Lauren E McCullough2, Alexandra J White3, Patrick T Bradshaw4, Xinran Xu5, Yoon Hee Cho6, Mary Beth Terry7, Susan L Teitelbaum8, Alfred I Neugut7,9, Regina M Santella7, Jia Chen8, Marilie D Gammon1. 1. Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina. 2. Department of Epidemiology, Emory University, Atlanta, Georgia. 3. Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina. 4. Division of Epidemiology, University of California, Berkeley, California. 5. Department of Biometrics, Roche Product Development in Asia-Pacific, Shanghai, China. 6. Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana. 7. Department of Epidemiology, Columbia University, New York, New York. 8. Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, New York. 9. Department of Medicine, Columbia University, New York, New York.
Abstract
BACKGROUND: The authors hypothesized that epigenetic changes may help to clarify the underlying biologic mechanism linking aspirin use to breast cancer prognosis. To the authors' knowledge, this is the first epidemiologic study to examine whether global methylation and/or tumor promoter methylation of breast cancer-related genes interact with aspirin use to impact mortality after breast cancer. METHODS: Prediagnosis aspirin use was assessed through in-person interviews within a population-based cohort of 1508 women diagnosed with a first primary breast cancer in 1996 and 1997. Global methylation in peripheral blood was assessed by long interspersed elements-1 (LINE-1) and the luminometric methylation assay. Promoter methylation of 13 breast cancer-related genes was measured in tumor by methylation-specific polymerase chain reaction and the MethyLight assay. Vital status was determined by the National Death Index through December 31, 2014 (N = 202/476 breast cancer-specific/all-cause deaths identified among 1266 women with any methylation assessment and complete aspirin data). Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% CIs, and the likelihood ratio test was used to evaluate multiplicative interactions. RESULTS: All-cause mortality was elevated among aspirin users who had methylated promotor of BRCA1 (HR, 1.67; 95% CI, 1.26-2.22), but not among those with unmethylated promoter of BRCA1 (HR, 0.99; 95% CI, 0.67-1.45; P for interaction ≤.05). Decreased breast cancer-specific mortality was observed among aspirin users who had unmethylated promotor of BRCA1 and PR and global hypermethylation of LINE-1 (HR, 0.60, 0.78, and 0.63, respectively; P for interaction ≤.05), although the 95% CIs included the null. CONCLUSIONS: The current study suggests that the LINE-1 global methylation and promoter methylation of BRCA1 and PR in tumor may interact with aspirin use to influence mortality after breast cancer.
BACKGROUND: The authors hypothesized that epigenetic changes may help to clarify the underlying biologic mechanism linking aspirin use to breast cancer prognosis. To the authors' knowledge, this is the first epidemiologic study to examine whether global methylation and/or tumor promoter methylation of breast cancer-related genes interact with aspirin use to impact mortality after breast cancer. METHODS: Prediagnosis aspirin use was assessed through in-person interviews within a population-based cohort of 1508 women diagnosed with a first primary breast cancer in 1996 and 1997. Global methylation in peripheral blood was assessed by long interspersed elements-1 (LINE-1) and the luminometric methylation assay. Promoter methylation of 13 breast cancer-related genes was measured in tumor by methylation-specific polymerase chain reaction and the MethyLight assay. Vital status was determined by the National Death Index through December 31, 2014 (N = 202/476 breast cancer-specific/all-cause deaths identified among 1266 women with any methylation assessment and complete aspirin data). Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% CIs, and the likelihood ratio test was used to evaluate multiplicative interactions. RESULTS: All-cause mortality was elevated among aspirin users who had methylated promotor of BRCA1 (HR, 1.67; 95% CI, 1.26-2.22), but not among those with unmethylated promoter of BRCA1 (HR, 0.99; 95% CI, 0.67-1.45; P for interaction ≤.05). Decreased breast cancer-specific mortality was observed among aspirin users who had unmethylated promotor of BRCA1 and PR and global hypermethylation of LINE-1 (HR, 0.60, 0.78, and 0.63, respectively; P for interaction ≤.05), although the 95% CIs included the null. CONCLUSIONS: The current study suggests that the LINE-1 global methylation and promoter methylation of BRCA1 and PR in tumor may interact with aspirin use to influence mortality after breast cancer.
Authors: Allen S Yang; Marcos R H Estécio; Ketan Doshi; Yutaka Kondo; Eloiza H Tajara; Jean-Pierre J Issa Journal: Nucleic Acids Res Date: 2004-02-18 Impact factor: 16.971
Authors: Yoon Hee Cho; Jing Shen; Marilie D Gammon; Yu-Jing Zhang; Qiao Wang; Karina Gonzalez; Xinran Xu; Patrick T Bradshaw; Susan L Teitelbaum; Gail Garbowski; Hanina Hibshoosh; Alfred I Neugut; Jia Chen; Regina M Santella Journal: Breast Cancer Res Treat Date: 2011-08-12 Impact factor: 4.872
Authors: Yanli Li; Theodore M Brasky; Jing Nie; Christine B Ambrosone; Susan E McCann; Peter G Shields; Maurizio Trevisan; Stephen B Edge; Jo L Freudenheim Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-11-08 Impact factor: 4.254
Authors: Aditya Bardia; Janet E Olson; Celine M Vachon; Deann Lazovich; Robert A Vierkant; Alice H Wang; Paul J Limburg; Kristin E Anderson; James R Cerhan Journal: Breast Cancer Res Treat Date: 2010-07-29 Impact factor: 4.872
Authors: Xinran Xu; Marilie D Gammon; Yujing Zhang; Timothy H Bestor; Steven H Zeisel; James G Wetmur; Sylvan Wallenstein; Patrick T Bradshaw; Gail Garbowski; Susan L Teitelbaum; Alfred I Neugut; Regina M Santella; Jia Chen Journal: Breast Cancer Res Treat Date: 2008-06-03 Impact factor: 4.872